2020
DOI: 10.4322/acr.2020.190
|View full text |Cite
|
Sign up to set email alerts
|

Epithelioid angiomyolipoma with tumor thrombus in IVC and right atrium

Abstract: Epithelioid angiomyolipoma is an uncommon subtype of renal angiomyolipoma associated with potentially malignant behavior and is considered a distinct entity by the World Health Organization classification of renal tumors. We present a case of an epithelioid variant of angiomyolipoma with extension into the renal vein, inferior vena cava reaching up to the right atrium. Pre-operatively, a diagnosis of renal cell carcinoma was considered based on imaging findings. Intra-operatively due to extensive adhesions, su… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 23 publications
0
2
0
Order By: Relevance
“…To date, only four cases of EAML with IVC thrombus have been reported; however, presurgical treatment was not performed. [14][15][16][17] Nephrectomy and thrombectomy were completed in three cases. [15][16][17] Clinicopathological prognostic factors were analyzed in two studies.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…To date, only four cases of EAML with IVC thrombus have been reported; however, presurgical treatment was not performed. [14][15][16][17] Nephrectomy and thrombectomy were completed in three cases. [15][16][17] Clinicopathological prognostic factors were analyzed in two studies.…”
Section: Discussionmentioning
confidence: 99%
“…[7][8][9][10][11][12][13] Unlike RCC, intravenous extension to inferior vena cava (IVC) is extremely rare in EAML. [14][15][16][17] Here, we report a case of EAML initially diagnosed as RCC, with a tumor thrombus extending to the inferior vena cava (IVC) presurgically treated with a combination of pembrolizumab and axitinib with a favorable response.…”
Section: Introductionmentioning
confidence: 99%